Switch to:
More From Other Websites
Are Regeneron, Sanofi Treading On Pfizer In Eczema? May 26 2017
Biotech And Pharma Industry And Stock News May 26 2017
Regeneron Presents Positive Phase II Data on HoFH Candidate May 25 2017
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene May 25 2017
Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive... May 24 2017
Theravance/Mylan Presents Phase III Data on COPD Candidate May 24 2017
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data May 24 2017
Blog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with... May 24 2017
Wide-Moat Roche Is Undervalued May 24 2017
Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis May 23 2017
​Sanofi Genzyme takes on world’s top-selling drugs with new approval May 23 2017
Charter's Rutledge, CBS's Moonves among highest-paid CEOs May 23 2017
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis May 23 2017
Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval May 22 2017
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately... May 22 2017
Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately... May 22 2017
Regeneron And Sanofi Have A Near-Term FDA Catalyst May 22 2017
ETFs with exposure to Regeneron Pharmaceuticals, Inc. : May 22, 2017 May 22 2017
Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session May 22 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK